- $75.28m
- $72.01m
- $32.03m
Brief: Electrocore, Inc-On Dec 20, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: electroCore Announces Issuance Of Two New U.S. Patents
Brief: Electrocore Announces Issuance Of Two New U.S. Patents
Brief: gammaCore Sapphire Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number By Belgian Pharmaceutical Association
electroCore, Inc. reports results for the quarter ended in September - Earnings Summary
electroCore, Inc. expected to post a loss of 7 cents a share - Earnings Preview
Brief: Electrocore Says Gammacore Non-Invasive Vagus Nerve Stimulation Improves Neurobehavioral Outcomes For Brain Injury
Brief: Electrocore, Inc. - QTRLY Loss Per Share $0.08
Brief: Electrocore Provides Select Second Quarter 2022 Financial Guidance
Brief: electrocore, Inc. Announces Study Of Gammacore Sapphire™ For The Treatment Of Post-Covid Syndrome
Brief: ElectroCore Announces Listing Transfer To Nasdaq Capital Market
Brief: electroCore Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
electroCore, Inc. reports results for the quarter ended in March - Earnings Summary
Brief: Electrocore Announces Record First Quarter 2022 Financial Results
electroCore, Inc. expected to post a loss of 7 cents a share - Earnings Preview
Brief: GammaCore nVNS Selected For Department Of Defense BOOST Program
Brief: electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
ElectroCore up on license deal with Japan's Teijin
electroCore, Inc. reports results for the quarter ended in December - Earnings Summary